153 related articles for article (PubMed ID: 37083962)
21. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
[TBL] [Abstract][Full Text] [Related]
22. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
23. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
Chiu CH; Wang WY; Chen HY; Liao PL; Jong GP; Yang TY
Cancer Sci; 2024 Jun; 115(6):2059-2066. PubMed ID: 38572526
[TBL] [Abstract][Full Text] [Related]
24. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1623-1631. PubMed ID: 37698621
[TBL] [Abstract][Full Text] [Related]
26. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
27. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
28. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
[TBL] [Abstract][Full Text] [Related]
29. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
[TBL] [Abstract][Full Text] [Related]
30. The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis.
Ma Y; Lin C; Cai X; Hu S; Zhu X; Lv F; Yang W; Ji L
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):877-886. PubMed ID: 35839519
[TBL] [Abstract][Full Text] [Related]
31. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
[TBL] [Abstract][Full Text] [Related]
32. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
[TBL] [Abstract][Full Text] [Related]
33. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
[TBL] [Abstract][Full Text] [Related]
34. Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).
Brunton S; Rozjabek HM; Pilon D; Lafeuille MH; Kamstra R; Wynant W; Bookhart BK; Lefebvre P
Curr Med Res Opin; 2019 Sep; 35(9):1607-1614. PubMed ID: 30964362
[No Abstract] [Full Text] [Related]
35. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study.
Ferwani P; Maldar A; Shah N; Chauhan P; Chadha M
J ASEAN Fed Endocr Soc; 2022; 37(2):5-8. PubMed ID: 36578886
[TBL] [Abstract][Full Text] [Related]
37. SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus.
Wong CKH; Tang EHM; Man KKC; Chan EWY; Wong ICK; Lam CLK
Diabetes Metab; 2021 Jul; 47(4):101196. PubMed ID: 33039672
[TBL] [Abstract][Full Text] [Related]
38. SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea.
Cho HJ; Lee E; Kim SS; Cheong JY
Sci Rep; 2024 Apr; 14(1):9761. PubMed ID: 38684838
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
[TBL] [Abstract][Full Text] [Related]
40. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]